Objectives We performed a systematic review and meta-analysis to evaluate the impact of
18 F-FDG PET, PET/CT, and PET/MRI on staging and management during the initial staging …

Current guidelines do not systematically recommend 18F-FDG PET/CT for breast cancer
staging; and the recommendations and level of evidence supporting its use in different …

We report a case series of biopsy-proven reactive axillary lymph nodes, which were avid on
FDG PET/CT in breast cancer patients post COVID-19 vaccination. With 4 cases presenting …

Background Axillary lymph node dissection (ALND) is frequently performed for node-positive
(cN+) breast cancer patients. Combining positron emission tomography/computed …

This article provides updates to readers based on the newly published Japanese Breast
Cancer Society Clinical Practice Guidelines for Breast Cancer Screening and Diagnosis …

Background In Ontario, there is no clearly defined standard of care for staging for distant
metastasis in women with newly diagnosed and biopsy-confirmed breast cancer whose …

Background: Metastatic staging imaging is not recommended for asymptomatic patients with
stage I–II breast cancer. Greater distant metastatic disease risk may warrant baseline …

PURPOSE: American Society for Clinical Oncology released the Choosing Wisely list in
2012, highlighting low-value procedures that lack evidence, advising against the use of …

Purpose Breast cancer is the most common malignancy accounting for 11.7% of all cancer
cases, with a rising incidence rate. Various diagnostic methods, including 18F-fluoro-2 …

Breast cancer is a common malignancy and a common cause of cancer-related mortality in
women. Pre-treatment workup of breast cancer does not routinely include positron emission …